Skip to main content
SpringerLink
Log in

Pharmacokinetic and Pharmacodynamic Factors Causing Variability in Response to Neuroleptic Drugs

  • Conference paper
Clinical Pharmacology in Psychiatry

Part of the book series: Psychopharmacology Series ((PSYCHOPHARM,volume 3))

Abstract

When a new psychotropic drug is introduced on the market with claims that it acts more specifically than the previous ones this has to be proven - not just in in vitro receptor binding systems and animal experiments - but also in patients. That can only be done by properly designed clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ahtee L, Mattila MJ, Vapaatalo HI (1967) The binding of some phenothiazines to human serum in vitro. Biochem Pharmacol 16: 2432–2435

    Article  PubMed  CAS  Google Scholar 

  • Alfredsson G, Lindberg M, Sedvall G (1982) The presence of 7-hydroxychlorpromazine in CSF of chlorpromazine-treated patients. Psychopharmacology (Berlin) 77: 376–378

    Article  CAS  Google Scholar 

  • Alfredsson G, Harnryd C, Wiesel F-A (1984) Effects of sulpiride and ehlorpromazine on depressive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacology (Berlin) 84: 237–241

    Article  CAS  Google Scholar 

  • Alfredsson G, Harnryd C, Wiesel FA (1985) Effects of sulpiride and ehlorpromazine on autistic and positive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacology (Berlin) 85: 8–13

    Article  CAS  Google Scholar 

  • Balant-Gorgia AE, Eisele R, Balant L, Garrone G (1984) Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur Arch Psychiatr Neurol Sci 234: 1–4

    Article  CAS  Google Scholar 

  • Bigelow LB, Kirch DG, Braun T, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ (1985) Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacol Bull 21: 66–68

    PubMed  CAS  Google Scholar 

  • Bolvig Hansen L, Larsen N-E (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berlin) 87: 16–19

    Article  Google Scholar 

  • Bolvig Hansen L, Larsen NE, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berlin) 78: 112–115

    Article  Google Scholar 

  • Brown WA, Silver MA (1985) Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate. J Clin Psychopharmacol 5: 143–147

    PubMed  CAS  Google Scholar 

  • Calil HM, Avery DH, Hollister LE, Creese I, Snyder SH (1979) Serum levels of neuroleptics measured by dopamine radio receptor assay and some clinical observations. Psychiatry Res 1:39— 44

    Google Scholar 

  • Cohen BM, Lipinski JF, Harris PQ, Pope HG, Friedman M (1980 a) Clinical use of the radioreceptor asssay for neuroleptics. Psychiatry Res 1: 173–178

    Google Scholar 

  • Cohen BM, Lipinski JF, Pope HG, Harris PQ, Altesman RI (1980 b) Neuroleptic blood levels and therapeutic effect. Psychopharmacology (Berlin) 70: 191–193

    Google Scholar 

  • Cross AJ, Crow TJ, Owen F (1981) 3H-Flupenthixol binding in post-mortem brains of schizophrenics: Evidence for a selective increase in dopamine D2 receptors. Psychopharmacology (Berlin) 74: 122–124

    Google Scholar 

  • Csernansky JG, Kaplan J, Holman CA, Hollister LE (1983) Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Psychopharmacology (Berlin) 81: 115–118

    Article  CAS  Google Scholar 

  • Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442

    PubMed  CAS  Google Scholar 

  • Dahl SG (1981) Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology 20: 1299–1302

    PubMed  CAS  Google Scholar 

  • Dahl SG (1982) Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 4: 33–40

    Article  PubMed  CAS  Google Scholar 

  • Dahl SG (1986) Plasma level monitoring of antipsychotic drugs: clinical utility. Clin Pharmacokinet 11: 36–61

    Article  PubMed  CAS  Google Scholar 

  • Dahl SG, Hall H (1981) Binding affinity of levomepromazine and two of its major metabolites to central dopamine and adrenergic receptors in the rat. Psychopharmacology (Berlin) 74: 101–104

    Article  CAS  Google Scholar 

  • Dahl SG, Strandjord RE (1977) Pharmacokinetics of ehlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448

    PubMed  CAS  Google Scholar 

  • Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R (1985) Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 21: 48–51

    PubMed  CAS  Google Scholar 

  • Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berlin) 73: 205–210

    Article  CAS  Google Scholar 

  • Freedberg KA, Innis RB, Creese I, Snyder SH (1979) Antipsychotic drugs: differential plasma protein binding and therapeutic activity. Life Sci 24: 2467–2474

    Article  PubMed  CAS  Google Scholar 

  • Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 4: 133–137

    Article  PubMed  CAS  Google Scholar 

  • Hals PA, Hall H, Dahl SG (1986) Phenothiazine drug metabolites: Dopamine D2 receptor, α1 and α2-adrenoceptor binding. Eur J Pharmacol 125: 373–381

    Article  PubMed  CAS  Google Scholar 

  • Hulka BS, Cassel JC, Kupper LL (1976) Disparities between medications prescribed and consumed among chronic disease patients. In: Lasagna L (ed) Patient Compliance. Futura Mount Kisco, New York, pp 123–152

    Google Scholar 

  • Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London, pp 111–174

    Google Scholar 

  • Kirch DG, Bigelow LB, Wyatt RJ (1985) The interpretation of plasma haloperidol concentrations. Arch Gen Psychiatry 42: 838–836

    PubMed  CAS  Google Scholar 

  • Krieglstein J, Lier F, Michaelis J (1972) Albumin binding and hydrophobic character of promazine and chlorpromazine metabolites. Arch Pharmacol 272: 121–130

    Article  CAS  Google Scholar 

  • Kucharski LT, Alexander P, Tune L, Coyle J (1984) Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology (Berlin) 82: 194–198

    Article  CAS  Google Scholar 

  • Larsson M, Axelsson R, Forsman A (1984) On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Curr Therapeutic Res 36: 1071–1088

    Google Scholar 

  • Lindenmayer JP, Smith D, Katz I (1984) Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. J Clin Psychiatry 45: 117–119

    PubMed  CAS  Google Scholar 

  • Linkowski P, Houbain P, Von Frenckell R, Mendlewicz J (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatr Neurol Sci 234: 231–236

    Article  CAS  Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology (Berlin) 81: 354–356

    Article  CAS  Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 a) Therapeutic blood levels of fluphenazine: Plasma or RBC determinations? Psychopharmacol Bull 20: 168–170

    Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 b) Fluphenazine plasma levels and clinical response. J Clin Psychiatry 45: 370–373

    Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 c) Clinical relevance of thiothixene plasma levels. J Clin Psychopharmacol 4: 155–157

    Google Scholar 

  • Mavroidis ML; Garver DL, Kanter DR, Hirschowitz J (1985) Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacol Bull 21: 62–65

    PubMed  CAS  Google Scholar 

  • Meitzer HY, Busch DA, Fang VS (1983) Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9: 271–283

    Article  Google Scholar 

  • Newman DC, Epperly M, Sangarasivam S, Maruta T, Homburger HA (1984) Neuroleptic levels in serum: clinical usefulness in schizophrenic patients. Clin Res 32:741 A

    Google Scholar 

  • Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103: 197–204

    Article  PubMed  CAS  Google Scholar 

  • Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 21: 59–61

    PubMed  CAS  Google Scholar 

  • Silverstone T, Cookson J, Ball R, Chin CN, Jacobs D, Lader S, Gould S (1984) The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. J Psychiatry Res 18: 255–268

    Article  CAS  Google Scholar 

  • Smith RC, Vroulis G, Misra CH, Schoolar J, De John C, Korivi P, Leelavahti DE, Arzu D (1980) Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs. Commun Psychopharmacol 4: 451–465

    PubMed  CAS  Google Scholar 

  • Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, De John C (1984 a) Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Arch Gen Psychiatry 41: 1044–1049

    Google Scholar 

  • Smith RC, Baumgartner R, Ravichandran GK, Shvartsburd A, Schoolar JC, Allen P, Johnson R (1984 b) Plasma and red cell levels of thioridazine and clinical response in schizophrenia. Psychiatry Res 12: 287–296

    Google Scholar 

  • Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M (1985) Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol Bull 21: 52–58

    PubMed  CAS  Google Scholar 

  • Tang SW, Glaister J, Davidson L, Toth R, Jeffries JJ, Seeman P (1984) Total and free plasma neuroleptic levels in schizophrenic patients. Psychiatry Res 13: 285–293

    Article  PubMed  CAS  Google Scholar 

  • Tune LE, Creese I, De Paulo JR, Slavney PR, Coyle JT, Snyder SH (1980) Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Am J Psychiatry 137: 187–190

    PubMed  CAS  Google Scholar 

  • Tune LE, Creese I, De Paulo JR, Slavney PR, Snyder SH (1981) Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenia. J Nerv Ment Dis 169: 60–63

    Article  PubMed  CAS  Google Scholar 

  • Van Putten T, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734

    Article  PubMed  Google Scholar 

  • Van Putten T, May PRA, Marder SR, Wilkins JN, Rosenberg BJ (1983) Plasma levels of thiothixene by radioreceptor assay: clinical usefulness. Psychopharmacology (Berlin) 79: 40–44

    Article  Google Scholar 

  • Van Putten T, Marder SR, May PRA, Poland RE, O’Brien RP (1985 a) Plasma levels, haloperidol and clinical response. Psychopharmacol Bull 21: 69–72

    Google Scholar 

  • Van Putten T, Marder SR, Mintz (1985 b) Plasma haloperidol levels: clinical response and fancy mathematics. Arch Gen Psychiatry 42: 835

    Google Scholar 

  • Wode-Helgodt B, Alfredsson G (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses. Psychopharmacology (Berlin) 73: 55–62

    Article  CAS  Google Scholar 

  • Wode-Helgodt B, Borg S, Fyrö B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58: 149–173

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Institute of Medical Biology, University of Tromsö, N-9001, Tromsö, Norway

    S. G. Dahl & P.-A. Hals

Authors
  1. S. G. Dahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P.-A. Hals
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Institute of Medical Biology, University of Tromsø School of Medicine, N-9001, Tromsø, Norway

    Svein G. Dahl Cand Real, Dr. Philos. (Professor of Pharmacology) (Professor of Pharmacology)

  2. Department of Clinical Pharmacology, School of Medicine, Odense University, DK-5000, Odense C, Denmark

    Lars F. Gram MD (Professor of Clinical Pharmacology) (Professor of Clinical Pharmacology)

  3. Clinical Neuroscience Branch, National Institute of Mental Health, Building 10, Room 4N214, 20205, Bethesda, MD, USA

    Steven M. Paul MD (Chief) (Chief)

  4. Section on Clinical Psychopharmacology, Laboratory of Clinical Science, Building 10, National Institute of Mental Health, 20205, Bethesda, MD, USA

    William Z. Potter MD, PhD (Chief) (Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Dahl, S.G., Hals, PA. (1987). Pharmacokinetic and Pharmacodynamic Factors Causing Variability in Response to Neuroleptic Drugs. In: Dahl, S.G., Gram, L.F., Paul, S.M., Potter, W.Z. (eds) Clinical Pharmacology in Psychiatry. Psychopharmacology Series, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71288-3_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71288-3_31

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71290-6

  • Online ISBN: 978-3-642-71288-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation